Co-Diagnostics, Inc. Vector Control Products Continue to Gain Acceptance Across the US
30 Julio 2019 - 5:30AM
Co-Diagnostics, Inc.
(Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today the
growing use of the Company’s Vector Smart™ NAM-W test by mosquito
abatement districts to identify the presence of West Nile virus
(WNV).
Press coverage from July 27 reported on mosquito
abatement districts already using the Company’s NAM-W test in their
pursuit of improving public health, and provided background on the
scope and mission of those districts. Diseases like WNV are carried
across the continent by migratory birds or other vectors, and are
then transmitted to humans or livestock by mosquitoes. The presence
of WNV has been reported in counties across the state of Utah this
mosquito season; local press as far away as New York City has
reported the same.
The article states:
"Usually, when sent to state labs, abatement
districts learn whether their mosquitoes test positive for West
Nile within one to two weeks. But Co-Diagnostics has developed a
test, called NAM-W, that the company says uses technology in a
faster, more affordable way, allowing districts to get results
within a day.”
In addition to West Nile, the multiplex
polymerase chain reaction (PCR) Vector Smart NAM-W also tests for
the presence of St. Louis encephalitis and western equine
encephalitis in mosquito populations. A Vector Smart NAM-E test is
currently planned which would identify eastern equine encephalitis,
a disease that kills roughly one-third of those infected and
typically leaves survivors with “mild to severe brain damage”
according to the CDC. Eastern equine encephalitis was recently
detected in Orange County, FL. The Company’s product line will also
soon be expanded to include a Vector Smart version of their
CE-marked Logix Smart™ ZDC (Zika, dengue, and chikungunya)
multiplex test, optimized for mosquito populations.
Co-Diagnostics CEO Dwight Egan commented, “The
recent article highlights the public health benefits of our
multiplex PCR solutions which allow for the detection of a variety
of diseases, making them the most competitive tests in this market,
and providing results within hours as opposed to a week or more.
Mosquito control activities are more accurate, efficient, and
effective the sooner disease-carrying mosquitoes are identified.
Deliveries of our unique and high-performance Vector Smart mosquito
tests to abatement districts and research institutions across the
country are already underway, and our pipeline for additional
vector control tests will continue to expand in response to the
needs of this growing market.”
More information about the Company’s vector
control solutions, pricing for the laboratory equipment packages,
and tests currently available or in development can be found on the
Company’s website at
http://codiagnostics.com/products/vector-solutions/.
About Co-Diagnostics,
Inc.:Co-Diagnostics, Inc., a Utah corporation, is a
molecular diagnostics company that develops, manufactures and
markets a new, state-of-the-art diagnostics technology. The
Company’s technology is utilized for tests that are designed using
the detection and/or analysis of nucleic acid molecules (DNA or
RNA). The Company also uses its proprietary technology to design
specific tests to locate genetic markers for use in industries
other than infectious disease and license the use of those tests to
specific customers.
Forward-Looking Statements:
This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company’s liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company’s products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company’s balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
Company
Contact:
Andrew
Benson
Head of Investor
Relations
+1
801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024